Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Lion Biotechnologies Inc Provides Update On Phase II Results For Metastatic Melanoma


Monday, 30 Sep 2013 08:01am EDT 

Lion Biotechnologies Inc announced that it is providing updated results from a Phase II trial for metastatic melanoma conducted by the National Cancer Institute (NCI) utilizing the tumor-infiltrating lymphocyte (TIL) technology currently licensed by the Company and being developed under a Cooperative Research and Development Agreement (CRADA) with the NCI. Steven A. Rosenberg, M.D., Ph.D., Chief of the NCI Surgery Branch, is the Principal Investigator on this study. The single-site trial included 93 patients in three cohorts. The long-term follow-up data reported by the NCI show an Objective Response (OR) rate of 49% for patients treated with TILs alone. Objective Response is Partial Response (PR) plus Complete Response (CR), with Partial Response defined as a reduction in tumor volume of greater than 50%. Of the 43 patients in this cohort, 12% showed Complete Response, and these patients continue to live more than seven years following treatment, with no measurable disease. Two additional cohorts of 25 patients each were treated with a combination of TILs and Total Body Irradiation (TBI). The cohort receiving TILs and 200 Gy TBI showed a 52% OR and 20% CR; the patients in the latter group continue to live more than seven years following treatment, with no measurable disease. 

Company Quote

6.72
-0.13 -1.90%
20 Aug 2014